Meeting
2014 Gastrointestinal Cancers Symposium
Phase I study of concomitant pemetrexed and cisplatin plus radiation in patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinomas.
Authors
Hani M. Babiker
University of Arizona Cancer Center, Tucson, AZ
Hani M. Babiker , Andrew I. Kovoor , Myke R. Green , Tomislav Dragovich , Thomas David Brown , Emad Elquza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00701857
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 145)
DOI
10.1200/jco.2014.32.3_suppl.145
Abstract #
145
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
First Author: Martin Reck
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2020 ASCO Virtual Scientific Program
Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.
First Author: Tithi Biswas
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour